Reports / Oncology Reports
The US multiple myeloma (MM) market is one of the more dynamic and complex therapeutic areas within the cancer landscape. New and emerging therapeutic options are rapidly changing oncologists’ views on drug combinations, sequencing, and goals of therapy.
Rapid turnaround monitor for highly dynamic healthcare segments
Retrospective analysis of 1,000+/- patient charts
Multiple Myeloma US (coming 2019)
Multiple Myeloma EU (coming 2019)